iLux Treatment for Meibomian Gland Dysfunction (MGD)

Status Completed

Clinical Trial Summary

The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.

Clinical Trial Description

Alcon Research, LLC, acquired TearFilm Innovations, Inc., in December 2018. This study was designed and conducted by TearFilm Innovations, Inc. The study results were collected, analyzed, and provided by TearFilm Innovations, Inc., to Alcon Research, LLC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03055650
Study type	Interventional
Source	Tear Film Innovations, Inc.
Contact
Status	Completed
Phase	N/A
Start date	December 7, 2015
Completion date	February 18, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Completed	`NCT04091581` - Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye	Phase 4
Active, not recruiting	`NCT04608942` - Refractory Meibomian Gland Dysfunction and Plasma Jet	N/A
Completed	`NCT03055897` - Tear Film Innovations iLux Safety Study	N/A
Completed	`NCT05536661` - Impact of Tear Substitute Use on Dry Eye in Gamers.	N/A
Completed	`NCT04658927` - Dextenza With ILUX for Treatment of MGD	Phase 4
Not yet recruiting	`NCT04711642` - Comprehensive Study on Dry Eye and Ocular Surface Disease Prior and After Cataract Surgery	Phase 3
Not yet recruiting	`NCT06158997` - Safety and Effectiveness of EyePeace on Signs and Symptoms of Dry Eye Disease	N/A
Completed	`NCT05331924` - Quality of Life Improvement in Dry Eye Patients After Intense Pulsed Light Therapy Compared to Punctal Plugs	N/A
Completed	`NCT04037969` - Comparison of Tear Evaporation Rate With DAILIES TOTAL1 and Biotrue ONEday	N/A